Full Text View
Tabular View
No Study Results Posted
Related Studies
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
This study has been terminated.
( Drug no longer being supplied by sponsor )
Study NCT00997243   Information provided by Ohio State University Comprehensive Cancer Center

First Received on October 16, 2009.   Last Updated on October 11, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions
Interventions listed in this trial
lintuzumab
5-azacytidine
Additional drug interventions recognized in this trial
Azacitidine
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Alison Walker
Seattle Genetics, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services